CRISPR/Cas9 a genomic engineering technology for treatment in ALS mouse models

Area of Science:

• Neuroscience
• Genetics
• Biotechnology

Background:

• Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease linked to numerous gene mutations.
• Most ALS cases are sporadic, but familial forms are associated with specific genetic mutations like SOD1, FUS, TARDBP, and C9orf72.
• Current understanding of ALS pathogenesis and potential treatments is limited.

Purpose of the Study:

• To review the application of CRISPR/Cas9 genome editing in studying ALS mouse models.
• To explore the potential of CRISPR/Cas9 in reversing ALS-associated mutations and understanding disease mechanisms.
• To discuss the limitations and future prospects of CRISPR/Cas9 technology in ALS research.

Main Methods:

• Review of current scientific literature on CRISPR/Cas9 applications in ALS mouse models.
• Analysis of studies utilizing CRISPR/Cas9 for gene editing to reverse or introduce mutations.
• Examination of in vivo delivery methods, such as adeno-associated vectors, for CRISPR/Cas9 in mouse models.

Main Results:

• CRISPR/Cas9 technology has demonstrated potential in reversing ALS-associated mutations in mouse models.
• The technique allows for the creation of specific mutations to investigate functional changes in genetic diseases like ALS.
• In vivo delivery of CRISPR/Cas9 via adeno-associated vectors can silence mutations, such as in the SOD1-linked ALS mouse model.

Conclusions:

• CRISPR/Cas9 is a powerful tool for advancing ALS research, offering new avenues for understanding disease mechanisms.
• Further research is needed to address limitations before CRISPR/Cas9 can be considered for clinical applications in ALS.
• The technology holds promise for developing novel therapeutic strategies for ALS patients.